Autoantibodies to Joint-Related Peptides Are Associated With Onset of Rheumatoid Arthritis in Presymptomatic Seronegative Individuals - Summary - MDSpire

Association of Autoantibodies to Joint-Related Peptides with the Development of Rheumatoid Arthritis in Asymptomatic Seronegative Patients

  • By

  • Outi Sareila

  • Linda Johansson

  • Anders Lundquist

  • Monica Leu Agelii

  • Lei Cheng

  • Yibo He

  • Erik Lönnblom

  • Maria Andersson

  • Jan Kihlberg

  • Anders Esberg

  • Inger Gjertsson

  • Rikard Holmdahl

  • Solbritt Rantapää-Dahlqvist

  • May 27, 2026

Share

Objective:

To investigate whether serum autoantibodies to joint-related peptides can predict the onset of rheumatoid arthritis (RA) in presymptomatic individuals with and without ACPA and RF.

Approach:
  • Study Design: A case-control study was conducted using the Medical Biobank of northern Sweden, analyzing plasma samples from presymptomatic individuals and matched control subjects.
  • Participants: 518 presymptomatic individuals (150 men and 368 women) were identified, with a median predating time of 4.7 years before RA symptom onset.
Key Findings:
  • Autoantibodies to joint-related peptides, termed 'JointIDs', may serve as predictive markers for RA onset.
  • The study highlights the potential of novel biomarkers in identifying individuals at high risk for developing RA.
Interpretation:

The findings suggest that specific autoantibodies could be utilized to predict RA in asymptomatic individuals, potentially aiding in early diagnosis and intervention.

Limitations:
  • The study is limited to a specific population cohort, which may affect generalizability.
  • Further research is needed to confirm the predictive value of identified autoantibodies in diverse populations.
Conclusion:

Identifying autoantibodies to joint-related peptides could enhance the ability to predict RA onset in at-risk individuals.

Original Source(s)

Autoantibodies to Joint-Related Peptides Are Associated With Onset of Rheumatoid Arthritis in Presymptomatic Seronegative Individuals

  • by Outi Sareila, Linda Johansson, Anders Lundquist, Monica Leu Agelii, Lei Cheng, Yibo He, Erik Lönnblom, Maria Andersson, Jan Kihlberg, Anders Esberg, Inger Gjertsson, Rikard Holmdahl, Solbritt Rantapää-Dahlqvist

  • May 27, 2026

Related Content

Joint Site May Influence RA Treatment Response

A Swiss registry study found that the wrist and second and third metacarpophalangeal joints consistently resolved more slowly than most other joints following biologic or targeted synthetic therapy.

Maresin-1 and maresin-2 as synovial fluid biomarkers in psoriatic, rheumatoid, and osteoarthritis

Autoreactivity vs autoimmunity: characteristics of autoantigen-specific CD4 T-cells in rheumatoid arthritis and health.